Literature DB >> 20346013

Advances in the understanding of MYC-induced lymphomagenesis.

Kay Klapproth1, Thomas Wirth.   

Abstract

Up to 70% of all human malignancies show elevated expression of MYC. MYC is a pleiotropic transcription factor involved in many aspects of cellular development and physiology. Besides direct regulation of target genes involved in proliferation and growth MYC is implicated in controlling the complex networks of microRNAs and apoptosis mediators. The mode of MYC deregulation varies between different tumor entities. In most types of cancer high MYC levels are secondary to alterations in cell signalling pathways, leading to enhanced proliferation of the transformed cells. In some haematological malignancies, like Burkitt lymphoma (BL) and subsets of diffuse large B-cell lymphomas, elevated MYC levels are a direct consequence of genomic aberrations involving the MYC locus. BL is considered the prime example for MYC-induced lymphomagenesis. In comparison to other haematological malignancies it has the highest MYC-expression and is often connected to Epstein-Barr virus (EBV) infection. Over the past five decades BL has provided an invaluable tool for the entire discipline of oncology, helping to decipher many aspects of tumor biology. This review summarizes recent advances in the research on MYC-induced lymphomagenesis, focusing on the regulation of microRNAs and apoptosis, and possible contributions of EBV for lymphoma development.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20346013     DOI: 10.1111/j.1365-2141.2010.08159.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  56 in total

1.  The clinical significance of 8q24/MYC rearrangement in chronic lymphocytic leukemia.

Authors:  Yan Li; Shimin Hu; Sa A Wang; Shaoying Li; Yang O Huh; Zhenya Tang; L Jeffrey Medeiros; Guilin Tang
Journal:  Mod Pathol       Date:  2016-02-26       Impact factor: 7.842

2.  P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma.

Authors:  Xuan J Wang; Carlos E Bueso-Ramos; Guilin Tang; Sa Wang; Yasuhiro Oki; Parth Desai; Joseph D Khoury; Roberto N Miranda; Zhenya Tang; Nishitha Reddy; Shaoying Li
Journal:  Mod Pathol       Date:  2016-10-14       Impact factor: 7.842

Review 3.  Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.

Authors:  Arantza Onaindia; L Jeffrey Medeiros; Keyur P Patel
Journal:  Mod Pathol       Date:  2017-06-30       Impact factor: 7.842

4.  The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma.

Authors:  D Lenze; L Leoncini; M Hummel; S Volinia; C G Liu; T Amato; G De Falco; J Githanga; H Horn; J Nyagol; G Ott; J Palatini; M Pfreundschuh; E Rogena; A Rosenwald; R Siebert; C M Croce; H Stein
Journal:  Leukemia       Date:  2011-06-24       Impact factor: 11.528

5.  Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma.

Authors:  Dashnamoorthy Ravi; Afshin Beheshti; Nasséra Abermil; Frank Passero; Jaya Sharma; Michael Coyle; Athena Kritharis; Irawati Kandela; Lynn Hlatky; Michail V Sitkovsky; Andrew Mazar; Ronald B Gartenhaus; Andrew M Evens
Journal:  Cancer Res       Date:  2016-03-17       Impact factor: 12.701

6.  Utilization of the Eμ-Myc mouse to model heterogeneity of therapeutic response.

Authors:  Rachel E Rempel; Xiaolei Jiang; Paul Fullerton; Tuan Zea Tan; Jieru Ye; Jieying Amelia Lau; Seiichi Mori; Jen-Tsan Chi; Joseph R Nevins; Daphne R Friedman
Journal:  Mol Cancer Ther       Date:  2014-10-27       Impact factor: 6.261

Review 7.  MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers.

Authors:  Nandini Dey; Brian Leyland-Jones; Pradip De
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

8.  Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma.

Authors:  Bing Xia; Le Zhang; Shan-Qi Guo; Xiao-Wu Li; Fu-Lian Qu; Hai-Feng Zhao; Lian-Yu Zhang; Bao-Cun Sun; James You; Yi-Zhuo Zhang
Journal:  World J Gastroenterol       Date:  2015-02-28       Impact factor: 5.742

Review 9.  Molecular genetics of B-precursor acute lymphoblastic leukemia.

Authors:  Charles G Mullighan
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

Review 10.  Double-hit mantle cell lymphoma with MYC gene rearrangement or amplification: a report of four cases and review of the literature.

Authors:  Reza Setoodeh; Stuart Schwartz; Peter Papenhausen; Ling Zhang; Elizabeth M Sagatys; Lynn C Moscinski; Haipeng Shao
Journal:  Int J Clin Exp Pathol       Date:  2013-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.